Efectividad y seguridad del tratamiento con inhibidores del factor de necrosis tumoral alfa en pacientes con artritis reumatoide

Arenere Mendoza, Mercedes; Navarro Aznárez, Herminia; Rabanaque Hernández, María José; Manero Ruiz, Francisco Javier.
Med. clín (Ed. impr.) ; 125(1): 35-36, jun. 2005. tab
Artículo en Es | IBECS (España) | ID: ibc-036650

Documentos relacionados

  1. Sex Differences in the Treatment of Psoriatic Arthritis: A Systematic Literature Review.
  2. Emerging drugs for psoriatic arthritis.
  3. [Proposal for biologic drugs therapy in rheumatoid arthritis].
  4. Drug-survival profiling of second-line biologic therapy in rheumatoid arthritis: Choice of another tumour necrosis factor inhibitor or a biologic of different mode of action?
  5. Paradoxical and bimodal immune-mediated dermatological side effects of TNF-α inhibitors: A comprehensive review.
  6. Clinical remission of psoriatic arthritis in patients receiving continuous biological therapies for 1 year: the experience of an outpatient dermatological clinic for psoriasis.
  7. The temporal association between hospital admissions, biological therapy usage and direct health care costs in rheumatoid arthritis patients.
  8. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs.
  9. Adherence to Anti-Tumor Necrosis Factor Therapy Administered Subcutaneously and Associated Factors in Patients With Rheumatoid Arthritis.
  10. The effect of biologic therapy for immune-mediated inflammatory diseases on clinical outcomes of COVID-19 in the greater Houston area: A retrospective chart review.